| Placebo group | ||||||
---|---|---|---|---|---|---|---|
 | Week 0 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 |
n | 70 | 68 | 66 | 64 | 62 | 60 | 60 |
SIgA secretion rate2(μg/5 min) | 319 ± 16 | 337 ± 21 | 333 ± 20 | 343 ± 21 | 348 ± 23 | 363 ± 22 | 334 ± 20 |
SIgA concentration (μg/mL) | 173 ± 13 | 170 ± 11 | 161 ± 12 | 159 ± 11 | 157 ± 11 | 165 ± 12 | 154 ± 11 |
Saliva flow rate (mL/5 min) | 2.5 ± 0.2 | 2.4 ± 0.2 | 2.7 ± 0.2 | 2.7 ± 0.2 | 2.8 ± 0.2 | 2.8 ± 0.2 | 2.9 ± 0.2 |
 | b240 group 1 | ||||||
 | Week 0 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 |
n | 76 | 75 | 70 | 72 | 62 | 70 | 66 |
SIgA secretion rate2(μg/5 min) | 297 ± 14 | 330 ± 20 | 357 ± 23 | 364 ± 27 | 366 ± 30 | 352 ± 23 | 359 ± 24 |
SIgA concentration (μg/mL) | 147 ± 8 | 165 ± 10 | 156 ± 9 | 149 ± 11 | 134 ± 8 | 144 ± 8 | 149 ± 9 |
Saliva flow rate (mL/5 min) | 2.3 ± 0.1 | 2.3 ± 0.2 | 2.6 ± 0.2 | 2.9 ± 0.2 | 3.0 ± 0.2 | 2.8 ± 0.2 | 2.7 ± 0.2 |